Access to anti-retroviral drugs, male in Switzerland

Switzerland: Access to anti-retroviral drugs, male was 90.0% in 2023. ▲ Rising

Latest (2023)
90.0%
Change on year
unchanged
World rank
13th
of 141 countries
All-time high
91.0%
in 2020
All-time low
31.0%
in 2000
Years of data
24
2000–2023

Access to anti-retroviral drugs, male in Switzerland, 2000–2023

4060801002000201120232000: 31 %2001: 36 %2002: 40 %2003: 45 %2004: 49 %2005: 53 %2006: 57 %2007: 60 %2008: 63 %2009: 66 %2010: 69 %2011: 71 %2012: 74 %2013: 75 %2014: 76 %2015: 77 %2016: 82 %2017: 89 %2018: 90 %2019: 89 %2020: 91 %2021: 90 %2022: 90 %2023: 90 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2023, access to anti-retroviral drugs, male in Switzerland stood at 90.0%.

That represents a change of up 20.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Switzerland peaked at 91.0% in 2020 and was at its lowest, 31.0%, in 2000.

That places Switzerland 13th out of 141 countries with data for 2023, putting it in the top 10%.

The long-run direction has been consistently rising across the 24 years of available data.

Access to anti-retroviral drugs, male in Switzerland, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Switzerland, 2000 to 2023.
Year % Change
2000 31.0%
2001 36.0% +16.1%
2002 40.0% +11.1%
2003 45.0% +12.5%
2004 49.0% +8.9%
2005 53.0% +8.2%
2006 57.0% +7.5%
2007 60.0% +5.3%
2008 63.0% +5.0%
2009 66.0% +4.8%
2010 69.0% +4.5%
2011 71.0% +2.9%
2012 74.0% +4.2%
2013 75.0% +1.4%
2014 76.0% +1.3%
2015 77.0% +1.3%
2016 82.0% +6.5%
2017 89.0% +8.5%
2018 90.0% +1.1%
2019 89.0% -1.1%
2020 91.0% +2.2%
2021 90.0% -1.1%
2022 90.0% +0.0%
2023 90.0% +0.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 50.0% 31.0% 66.0% 10
2010s 79.2% 69.0% 90.0% 10
2020s 90.2% 90.0% 91.0% 4

Countries ranked near Switzerland

  1. 11 Botswana 92.0% compare
  2. 12 Spain 91.0% compare
  3. 13 Burundi 90.0% compare
  4. 13 Malawi 90.0% compare
  5. 13 Namibia 90.0% compare

See the full ranking of 160 places →

More gender data for Switzerland

All data for Switzerland →

Frequently asked questions

What is access to anti-retroviral drugs, male in Switzerland?
Access to anti-retroviral drugs, male in Switzerland was 90.0% in 2023, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Switzerland?
The highest recorded value was 91.0% in 2020.
What is the lowest access to anti-retroviral drugs, male recorded in Switzerland?
The lowest recorded value was 31.0% in 2000.
How does Switzerland rank for access to anti-retroviral drugs, male?
Switzerland ranks 13th out of 141 countries with data for 2023.
Is access to anti-retroviral drugs, male rising or falling in Switzerland?
Over the last ten years it is up 20.0%. The long-run trend across the full record is rising.
Where does this Switzerland data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Switzerland. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/switzerland/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/switzerland/">Access to anti-retroviral drugs, male in Switzerland</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.